Vascular Group

Publication

We proudly announce the publication of our first paper in Journal of Biological Chemistry (JBC) related to our chlorotoxin analogue (CTXA) development. We use our patented chlorotoxin analogues for targeting CAR-T cells to cure patient suffering from glioblastoma multiforme (GBM). Publication link: https://www.jbc.org/article/S0021-9258(23)02026-4/fulltext

VRG Therapeutics demonstrates in vivo efficacy with a selective Kv1.3 inhibitor developed for autoimmune diseases

Press release BUDAPEST, HUNGARY, May 26, 2023/ EINPresswire.com/ — VRG Therapeutics, a biotechnology R&D company focused on peptide-based pharmaceuticals and cellular & gene therapy (CGT) products has announced that their exceptionally selective Kv1.3 inhibitor peptide showed efficacy in a delayed-type hypersensitivity animal model. VRG Tx’s lead compound has been developed on the company’s ISEP platform […]

Project news

Our chlorotoxin-analog (CTXA) targeted CAR T asset is not only strong by scientific means but also holds strong IP protection. The project reached an important milestone: we received the International Preliminary Report on Patentability for our patent application (PCT/HU2021/050075). The result is: all claims have been accepted in terms of all requirements of patentability! We’ll […]

Pathfinder Open grant (HORIZON-EIC-2023-PATHFINDEROPEN-01-01)

VRG is planning to apply for a Pathfinder Open grant (HORIZON-EIC-2023-PATHFINDEROPEN-01-01) and looking for partners active on the following fields: – Development and production of AAV-s for viral transduction of genetic material to CNS neurons.– Development and production of electrodes to be applied in neurosurgery or devices for microinjection. The device we envisage would be […]

BIO-Europe 2022 Leipzig

We are happy to share that we participate Bio-Europe on October 24–26, 2022 in Leipzig, Germany. We are looking for investors/partners for our forerunning GBM targeting CTXA-CAR-T project. In addition, you may learn more about our gene therapy based chemogenetic program in CNS indication which is now available for initial funding.Meet our Head of CMC […]

Innovation Marketplace and Career Day of Eötvös Loránd University, Faculty of Science

We’re expanding our network towards academic research: VRG will join Innovation Marketplace and Career Day of Eötvös Loránd University, Faculty of Science on 13 October. Our BD and Project Manager, Tamás Kitka will give a company presentation and participate a roundtable discussion. Looking forward to meet our future research partners there! Cell and Gene Meeting […]

VRG announces major milestone in chlorotoxin targeted CAR T therapy in glioblastoma

Press release DREADDs are exclusively activated by their pharmaceutical ligand, the so-called actuator. CNS-delivered artificial DREADDs have no physiological effects without their actuator, offering a flexible and adaptive control of the timing and intensity of the effect. This technique can be employed to develop a safe, adjustable alternative of current neurosurgery techniques, such as deep […]

Vascular Research Group News

2021 October 15Vascular Research Group at the annual meeting of the Peptidkémiai MunkabizottságVascular Research Group (VRG) presented its progress on CTX analogue development at the annual meeting of the Peptidkémiai Munkabizottság (MTA). The annual meeting of the Peptidkémiai Munkabizottság (Hungarian Academy of Sciences) took place between 2021 October 11 and 13, and VRG got the […]